Results 71 to 80 of about 2,191 (125)

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Lung Cancer: Targets and Therapy
Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou ...
Lee ATM, Ou SI
doaj  

Targeted therapies in the management of advanced medullary thyroid cancer. [PDF]

Oncologist
Arain HA, Izhar A, Caretti R, Chen H, Vodopivec DM.   +4 more
europepmc   +1 more source

Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer. [PDF]

Pharmacoecon Open
Wu YS, Burger EA, Holmboe F, Bangum M, Oteiza F, Bugge C, Sæther EM, Aas E.   +7 more
europepmc   +1 more source

Dynamic clonal evolution of multiple bypass resistance mechanisms in <i>EGFR</i>-mutant lung adenocarcinoma: a case report. [PDF]

Front Oncol
Zhang Q, Yin X.
europepmc   +1 more source

Selpercatinib as First-Line Therapy in a 9-Month-Old Infant With Metastatic <i>RET</i> Fusion-Positive Sarcoma: A Case Report. [PDF]

JCO Precis Oncol
Mast AS, Leuschner U, Schulte S, Mezger M, Ebinger M.   +4 more
europepmc   +1 more source

Response to Selpercatinib in a <i>CCDC6-RET</i> Lung Adenocarcinoma with an Acquired Novel <i>RET</i> p.L730_G731insL After Progression on Pralsetinib: A Case Report. [PDF]

Lung Cancer (Auckl)
Tian C, Zou Y, Liu J, Zhao J, Tian S, Liu Y, Wang G.   +6 more
europepmc   +1 more source

Durable response to selpercatinib in HOOK3-RET fusion positive, α-fetoprotein producing metastatic pancreatic ductal adenocarcinoma with intestinal-type differentiation. [PDF]

Oncol Lett
Sandhu HS, Natarajan A, Joshi S.
europepmc   +1 more source

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma. [PDF]

JCO Precis Oncol
Milewski D, Fallatah A, Groff M, Rahmy A, Khan SR, Okafor C, Glassberg B, Chou HC, Heselmeyer-Haddad K, Wangsa D, Wangsa D, Kim Y, Isanogle K, Song Y, Zhang X, Thomas C, Difilippantonio S, Park JI, Wei JS, Hawley RG, Glod J, Khan J.   +21 more
europepmc   +1 more source

RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases. [PDF]

Cell Death Dis
Regua AT, Bindal S, Najjar MK, Tran PL, Cha J, Shams SS, Lo HW.   +6 more
europepmc   +1 more source

Ectopic ACTH Production in Medullary Thyroid Carcinoma-A Study of Two Cases. [PDF]

Case Rep Endocrinol
Bränström R, Hedberg F, Huisman M, Petersson M, Jerning C, Shabo I, Goldstein DJM, Larsson M, Juhlin CC.   +8 more
europepmc   +1 more source